NASDAQ:PLRX Pliant Therapeutics Q3 2024 Earnings Results & Report $1.02 +0.02 (+2.00%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$1.03 +0.01 (+0.59%) As of 10/9/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Pliant Therapeutics beat analyst earnings expectations in its Q3 2024 results, released November 7, 2024. The company reported EPS of -$0.95 versus the -$0.99 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2024Report DateNovember 7, 2024TimeAfter Market ClosesConference Call4:00 PM ET Pliant Therapeutics EPS ResultsActual EPS-$0.95Consensus EPS -$0.99Beat/MissBeat by +$0.04One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersPliant Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsPliant Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Pliant Therapeutics Q3 2024 Earnings FAQ Did Pliant Therapeutics beat earnings estimates for Q3 2024? Pliant Therapeutics (NASDAQ:PLRX) reported earnings of -$0.95 per share for Q3 2024, beating the consensus estimate of -$0.99. The report was announced on Thursday, November 7, 2024. When is Pliant Therapeutics' next earnings date? Pliant Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Pliant Therapeutics on the company's earnings history page. Pliant Therapeutics Earnings HeadlinesPliant Therapeutics, Inc. (NASDAQ:PLRX) Stock Rated "Reduce" by Wall Street BrokeragesOctober 7 at 4:15 AM | americanbankingnews.comPLRX’s FORTIFY Trial: Early Oncology Bet With Upside for Immune-Oncology InvestorsOctober 2, 2026 | tipranks.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.October 10 at 1:00 AM | Weiss Ratings (Ad)Pliant Therapeutics Names David Raben As CMO To Lead PLN-101095 DevelopmentOctober 1, 2026 | rttnews.comPliant Therapeutics Appoints David Raben, M.D., as Chief Medical OfficerSeptember 30, 2026 | globenewswire.comPliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from S&P Global BMI IndexSeptember 21, 2026 | marketscreener.comMSee More Pliant Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pliant Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pliant Therapeutics and other key companies, straight to your email. Email Address About Pliant TherapeuticsPliant Therapeutics (NASDAQ:PLRX) is a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic diseases. The company uses its expertise in integrin biology to discover and develop medicines intended to address the underlying mechanisms that contribute to tissue scarring and organ dysfunction. Pliant’s leading investigational product is bexotegrast, an oral, small-molecule inhibitor designed to selectively target the alphaVbeta6 and alphaVbeta1 integrins. The therapy has been studied in conditions including idiopathic pulmonary fibrosis, a progressive lung disease, and primary sclerosing cholangitis, a chronic liver disease. The company has also developed additional preclinical and clinical programs aimed at fibrotic and related diseases. Founded in 2015, Pliant Therapeutics is headquartered in South San Francisco, California, and its activities are primarily centered on research and clinical development. The company’s leadership has included Bernard Coulie, M.D., Ph.D., as president and chief executive officer. Pliant’s therapies remain investigational and are subject to clinical testing and regulatory review.View Pliant Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
